EndTB Clinical Trial Enrolls 750 Patients
Enrollment signals step forward in global effort to end tuberculosis
Posted on Oct 21, 2021
The race to find a safer, shorter treatment for one of the world’s deadliest infectious diseases just advanced to the next level.
The endTB project has enrolled 750 patients across four continents in a clinical trial aiming to find safer, shorter, and effective treatments for multidrug-resistant tuberculosis (MDR-TB).
Partners In Health is among the organizations leading the clinical trial, along with Médecins Sans Frontières, Interactive Research and Development, and financial partner Unitaid.
The clinical trial comes as part of the endTB project, which was launched in 2016 to revolutionize treatment for MDR-TB patients. Enrollment was completed earlier this month, even as COVID-19 paused hundreds of clinical trials and caused a reduction in TB diagnosis and treatment worldwide—making the milestone even more notable.
MDR-TB is an airborne, infectious disease that has become resistant to standard antibiotics. Each year, 500,000 people fall sick with MDR-TB and nearly 200,000 die, according to the World Health Organization.
Existing treatment regimens for MDR-TB are long and painful, requiring daily injections and taking as long as 2 years to complete.
The clinical trial compares five new treatment regimens, which include bedaquiline and delamanid—two new TB drugs developed in recent years—in combination with other existing oral TB drugs. While these new drugs were approved by regulators as individual medications, they hadn’t yet been tested in combination with other drugs, as a treatment for MDR-TB.
These new regimens could shorten the treatment timeline to as little as six months and wouldn’t require daily injections—an outcome that would be revolutionary for patients living with MDR-TB.
“Shortened regimens, which don’t require daily injections, represent a major advantage to patients and health systems,” says Dr. Carole Mitnick, senior TB researcher with PIH and co-principal investigator of the trial. “We launched the endTB trial to ensure that we have the strongest possible evidence for safe, effective, shortened, injectable-sparing regimens that can be made available worldwide.”
A Global Effort
EndTB’s movement to discover safer, shorter treatments for MDR-TB spans four continents.
Patients were recruited for the Phase III randomized controlled trial from seven countries, including Kazakhstan, Lesotho, and Peru—countries where PIH works and where MDR-TB is an ongoing threat.
“In Peru, we are very proud to be part of the endTB clinical trial and to actively contribute, so Peruvian patients have access to oral and shortened treatments for multidrug-resistant TB,” says Dr Leonid Lecca, executive director of Socios En Salud, as PIH is known in Peru. “Every day we see a growing interest from health care professionals and among the community to access these treatments.”
The clinical trial aimed to enroll a diverse group of patients to ensure that clinicians would have the data they need to best care for vulnerable populations.
“The endTB clinical trial from the initial design strived to have high diversity in terms of different ages, geography, cultures, and ethnicity,” says Dr. Michael Rich, endTB project leader for PIH. “The endTB trial takes place across the African, Asian, European, and South American populations and enrolls people affected by comorbidities like HIV, Hepatitis C, or diabetes.”
The trial also aimed to shorten the research and development process, where scientifically prudent, getting potentially lifesaving drugs to patients faster. Instead of testing the different regimens sequentially—a process that could take 10 years or longer—PIH and partners used adaptive randomization, a method that allows for a relatively small sample size, requires fewer resources, and may enable dramatic improvements in treatment over shorter periods of time.
To further strengthen the research process, PIH and partners also helped train staff at clinical sites, allowing for more research, faster recommendations, and better treatment in the future.
The results of the clinical trial will be available in 2023 and will be relevant for a wide range of patients living with MDR-TB.
For more information, read endTB’s press release.